Canada Pension Plan Investment Board Purchases 953,551 Shares of Pfizer Inc. $PFE

Canada Pension Plan Investment Board lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 14.1% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,731,197 shares of the biopharmaceutical company’s stock after buying an additional 953,551 shares during the quarter. Canada Pension Plan Investment Board owned about 0.14% of Pfizer worth $186,167,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Handelsbanken Fonder AB lifted its stake in Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after purchasing an additional 232,528 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Pfizer by 15.7% during the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after purchasing an additional 745,213 shares during the period. Leuthold Group LLC purchased a new stake in Pfizer in the second quarter worth $4,887,000. North Dakota State Investment Board bought a new stake in shares of Pfizer in the fourth quarter valued at $5,348,000. Finally, Park National Corp OH raised its stake in shares of Pfizer by 332.1% in the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after buying an additional 186,053 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.8%

Pfizer stock opened at $28.33 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The stock has a market cap of $161.47 billion, a P/E ratio of 37.28 and a beta of 0.34. The firm’s fifty day moving average price is $25.44 and its 200-day moving average price is $26.29.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the business earned $0.78 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PFE shares. Citigroup lifted their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Bank of America cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and lowered their price target for the company from $32.00 to $28.00 in a research report on Monday, July 6th. BMO Capital Markets dropped their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Finally, Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has started a European Medicines Agency review for its Lyme disease vaccine. The review is an important regulatory step that could expand Pfizer’s longer-term vaccine portfolio, although it does not guarantee approval or near-term revenue. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Positive Sentiment: Recent comparisons with Bristol Myers Squibb suggest Pfizer’s valuation, diversification and oncology portfolio may offer an attractive risk-reward profile. This supports the view that the stock could benefit if new medicines successfully offset declining legacy-product sales. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Analysts are focused on Pfizer’s post-second-quarter pipeline and whether upcoming medicines can reset the company’s growth trajectory. The opportunity is meaningful because Pfizer recently exceeded quarterly earnings and revenue expectations, but execution remains key. How Is Pfizer Shaping Its S&P 500 Pipeline After Q2?
• Neutral Sentiment: Pfizer’s dividend remains appealing to income-oriented investors, but comparisons with Abbott Laboratories emphasize that Pfizer offers more turnaround potential while Abbott has a steadier dividend-growth record and broader diversification. Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
• Neutral Sentiment: Brokerages collectively rate Pfizer “Hold,” indicating that analysts see potential value but lack a strong consensus catalyst for a decisive re-rating. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Investor caution persists over Pfizer’s need to restore growth before major patent expirations arrive. Articles discussing new medicines frame the pipeline as necessary to counterbalance expected pressure on established products, limiting enthusiasm until launches and approvals produce measurable results. Can New Medicines Reset the Growth Story?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.